Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Gastrointestinal 2Dermatologic 2Thoracic 1Other solid neoplasm 1Lymphoid 1Genitourinary 1CNS 1Breast 1

Conditions

Hodgkin Disease 36Lymphoma 34Lymphoma, Non-Hodgkin 24Lymphoma, Large B-Cell, Diffuse 24Lymphoma, Follicular 18Lymphoma, B-Cell 16Recurrence 15Melanoma 14Neoplasms 12Mycosis Fungoides 9Lymphoma, T-Cell 9Breast Neoplasms 9Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 7Lymphoma, T-Cell, Cutaneous 7Lymphoma, B-Cell, Marginal Zone 7Head and Neck Neoplasms 7Sezary Syndrome 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Lymphoma, Mantle-Cell 6Lung Neoplasms 6Carcinoma, Renal Cell 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Neoplasm Metastasis 5Lymphoma, T-Cell, Peripheral 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4

Interventions

tazemetostat 2pembrolizumab 1interferon gamma-1b 1Rifampin 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Itraconazole 1Interferon-gamma 1Immunotherapy, Adoptive 1Immunotherapy 1Imatinib Mesylate 1Drug Therapy 1CLR1404 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Synovial × pembrolizumab × Lymphoid × Clear all
NCT03063632 2023-10-25

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
28 enrolled 15 charts
LymphoidSarcoma

Mycosis Fungoides, Sezary Syndrome, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡